Event overview and recent share performance

Elevance Health (ELV) has recently drawn investor attention after a period of weaker share performance, with the stock showing a 16.5% decline year to date and a 30.8% decline over the past year.

Over the past month, Elevance Health has recorded a 14.7% decline, alongside a 14.5% decline over the past 3 months, prompting closer scrutiny of how its current valuation lines up with recent financial results.

At a share price of $295.75, Elevance Health has recently seen weaker momentum, with a 1 year total shareholder return of 30.8% decline and a 5 year total shareholder return of 9.79% decline. At the same time, the 7 day share price return of 4.62% contrasts with a 30 day share price return of 14.72% decline and a 3 year total shareholder return of 33.92% decline, pointing to pressure that appears more entrenched than the latest short term bounce suggests.

If you are reassessing your exposure to healthcare, it could be a good moment to broaden your watchlist and check out 36 healthcare AI stocks

With Elevance Health trading at $295.75, alongside an indicated intrinsic discount of 70.58%, the key question is simple: are you looking at a genuine value opportunity, or is the market already pricing in its future growth?

Most Popular Narrative: 24.3% Undervalued

According to the most followed narrative for Elevance Health, the fair value estimate of $390.54 sits well above the last close of $295.75, which is where the current 24.3% discount comes from.

As a potential growth investment, Elevance Health is described as offering a mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. Near-term risks such as Medicaid enrollment declines and cost pressures are cited as challenges, while its diversified revenue base and focus on innovation are viewed as sources of resilience. Strategic timing and close monitoring of market and operational trends are highlighted as important considerations for investors evaluating its growth potential over the next 1-3 years.

Want to see what sits behind that valuation gap? The narrative focuses on earnings power, profit margins, and where future cash flows could settle. Curious which assumptions really influence that $390.54 figure?

Result: Fair Value of $390.54 (UNDERVALUED)

However, there are still clear pressure points, with Medicaid membership declines and elevated medical costs both capable of undermining the current undervaluation narrative.

Next Steps

With sentiment clearly mixed, this is a moment to look at the numbers yourself and decide how compelling Elevance Health really is. To see what investors are optimistic about and weigh those positives against the risks, review the 5 key rewards

Looking for more investment ideas?

Before you move on, give yourself the chance to spot a few fresh ideas that could complement or challenge your view on Elevance Health.

• Target quality first and scan for companies with healthy finances using the solid balance sheet and fundamentals stocks screener (42 results)
• Hunt for potential bargains by reviewing companies trading on what may be appealing valuations in the 49 high quality undervalued stocks
• Strengthen your opportunity set by checking a curated screener containing 27 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.